Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Alkermes Plc (ALKS)  
$24.68 0.24 (0.98%) as of 4:30 Fri 4/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 183,678,000
Market Cap: 4.53(B)
Last Volume: 775,760 Avg Vol: 773,595
52 Week Range: $23.37 - $33.63
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Delivery

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  581
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 35,000
Total Buy Value $0 $0 $0 $815,735
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 15,666 15,666 89,488 206,962
Total Sell Value $454,291 $454,291 $2,700,159 $6,056,962
Total People Sold 3 3 4 6
Total Sell Transactions 3 3 7 12
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 2018
  Page 10 of 81  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2022-02-22 4 D $25.01 $61,575 D/D (2,462) 232,306     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2022-02-22 4 OE $0.00 $0 D/D 5,543 234,768     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2022-02-22 4 D $25.01 $51,245 D/D (2,049) 59,906     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2022-02-22 4 OE $0.00 $0 D/D 6,969 61,955     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2022-02-22 4 D $25.01 $69,878 D/D (2,794) 87,915     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2022-02-22 4 OE $0.00 $0 D/D 9,503 90,709     -
   Nichols Christian Todd SVP, Chief Commercial Officer   •       •      –    2022-02-22 4 D $25.01 $51,045 D/D (2,041) 26,038     -
   Nichols Christian Todd SVP, Chief Commercial Officer   •       •      –    2022-02-22 4 OE $0.00 $0 D/D 6,969 28,079     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2022-02-21 4 D $25.08 $50,712 D/D (2,022) 21,479     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2022-02-21 4 OE $0.00 $0 D/D 6,875 23,501     -
   Pops Richard F Director and CEO, Alkermes plc   •       •      –    2022-02-21 4 D $25.08 $360,801 D/D (14,386) 865,556     -
   Pops Richard F Director and CEO, Alkermes plc   •       •      –    2022-02-21 4 OE $0.00 $0 D/D 32,400 879,942     -
   Gaffin David Joseph SVP, CLO, Alkermes, Inc.   •       •      –    2022-02-21 4 D $25.08 $50,712 D/D (2,022) 92,623     -
   Gaffin David Joseph SVP, CLO, Alkermes, Inc.   •       •      –    2022-02-21 4 OE $0.00 $0 D/D 6,875 94,645     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2022-02-21 4 D $25.08 $64,882 D/D (2,587) 229,225     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2022-02-21 4 OE $0.00 $0 D/D 5,825 231,812     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2022-02-21 4 D $25.08 $35,413 D/D (1,412) 54,986     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2022-02-21 4 OE $0.00 $0 D/D 4,800 56,398     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2022-02-21 4 D $25.08 $35,413 D/D (1,412) 81,206     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2022-02-21 4 OE $0.00 $0 D/D 4,800 82,618     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2022-02-20 4 D $25.08 $74,387 D/D (2,966) 16,626     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2022-02-20 4 OE $0.00 $0 D/D 10,096 19,592     -
   Gaffin David Joseph SVP, CLO, Alkermes, Inc.   •       •      –    2022-02-20 4 D $25.08 $51,690 D/D (2,061) 87,770     -
   Gaffin David Joseph SVP, CLO, Alkermes, Inc.   •       •      –    2022-02-20 4 OE $0.00 $0 D/D 7,036 89,831     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2022-02-20 4 D $25.08 $59,389 D/D (2,368) 225,987     -
  2018 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 10 of 81
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us